Stocktoria
4D Molecular Therapeutics, Inc. FDMT
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-12-11
Chart by TradingView
3/9
Piotroski F — financial health
6.96
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $85.2M | $37,000 | $20.7M | $3.1M | $18.0M |
| Operating income | -$159.5M | -$187.8M | -$112.9M | -$110.0M | -$71.3M |
| Net income | -$140.1M | -$160.9M | -$100.8M | -$107.5M | -$71.3M |
| Operating cash flow | -$109.1M | -$134.6M | -$75.8M | -$86.7M | -$69.1M |
| Free cash flow | -$109.6M | -$138.4M | -$78.6M | -$98.2M | -$78.2M |
| Total assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M |
| Total liabilities | $61.0M | $49.8M | $32.1M | $30.5M | $34.4M |
| Shareholders' equity | $505.7M | $510.6M | $307.8M | $231.3M | $319.1M |
| Ratios | |||||
| Operating margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% |
| Net margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% |
| FCF margin | -128.6% | -373975.7% | -379.1% | -3139.1% | -433.8% |
| Return on assets | -24.7% | -28.7% | -29.7% | -41.1% | -20.2% |
| Return on equity | -27.7% | -31.5% | -32.8% | -46.5% | -22.3% |
| Current ratio | 9.39 | 14.92 | 15.65 | 14.02 | 15.69 |
| Revenue growth | 230194.6% | -99.8% | 562.3% | -82.7% | 35.0% |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 578,265 | $5.4M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.96 (safe)
- Working capital / assets 0.651
- Retained earnings / assets -1.264
- EBIT / assets -0.282
- Equity / liabilities 8.283
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001650648 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.